WebJun 29, 2024 · Since the introduction of Chapter 18A in 2024, which allows listing for pre-revenue biotech companies, the HKEx has cultivated the development of a viable eco system for fundraising of healthcare and life sciences companies, which has generated a steady flow of listings of biotech companies. WebJul 3, 2024 · HKEX closed 2024 with a total of 92 biotech and healthcare listings on its main board, raising a total of HKD 255 billion (USD 32.6 billion) since the launch of the internal reforms. The figure includes 48 pre-revenue biotech companies that have listed under Chapter 18A, raising a total of HKD 112.6 billion (USD 14.4 billion).
Updated HKEx Guidance for Biotech Companies Listed Under …
WebListings of Pre-revenue Biotech Companies on HKEx under Chapter 18A of the Listing Rules In addition to technology, the Healthcare and Life Sciences sector is steadily taking shape in the Hong Kong IPO market with the help of biotech companies thanks to the addition of Chapter 18A, which allowed the listing of pre-revenue biotech companies on … WebJan 14, 2024 · Bio-tech Listings on HKEX (18A) 1. Introduction. In light of the prevalence of biotechnology in such an era o innovation and technology, the Hong Kong Stock Exchange (“the Exchange”) published Chapter 18A of the Main Board Listing Rules (“Chapter 18A”) on 24 April 2024. The introduction of Chapter 18A aims to assist pre-revenue Biotech ... bra size order smallest to largest
An Easier Road to a Hong Kong Listing for Biotech Companies
WebDec 9, 2024 · The four companies listed under the HKEX’s Chapter 18A – a tool introduced in 2024 that allows pre-revenue biotech companies to raise funding – so far in 2024 are Lepu Biopharma, Jiangsu Recbio Technologies, Rainmed Medical and Biocytogen Pharmaceuticals. The key requirements contained in Chapter 18A, and the related … WebApr 24, 2024 · The Exchange will add new Chapter 18A to the Main Board Listing Rules (LR) ... Existing shareholders are allowed to subscribe for IPO shares to avoid their shareholdings being diluted under HKEx Guidance … Webunder Chapter 18A The Hong Kong Stock Exchange (HKEx) issued new and updated guidance letters in April 2024 to assist pre-revenue Biotech companies applying to list under Chapter 18A of the Main Board Listing Rules (Chapter 18A). The latest guidance follows a review by HKEx of how Chapter 18A operates and comprises: bra size in inches chart